“We believe that this ICGEB designed vaccine is a game-changer,” Navin Khanna, who leads the dengue vaccine research at ICGEB, said on Monday. Developing a dengue vaccine is a complicated as it is a single strand RNA virus that breeds inside the human body with a chance of contracting a more deadly dengue infection the second time. Currently, the only dengue vaccine recommended by the World Health Organization is Dengvaxia, developed by Sanofi Pasteur. Several other dengue vaccine candidates are under development with a handful in India as well. The ICGEB research is supported by the Wellcome Trust, India’s department of biotechnology and the Indo-US Vaccine Programme.

Source: Hindustan Times November 28, 2017 09:56 UTC